Search

Displaying results 2891 - 2900 of 4591 in total
  1. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.

  2. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the Un...

  3. Drug

    Talsupram

    go.drugbank.com/drugs/DB09191
    Experimental

    It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].

  4. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    [A193506] SEP-363856 was developed by Sunovion pharmaceuticals. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5

  5. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  6. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family.

  7. Drug

    Sea salt

    go.drugbank.com/drugs/DB11266
    Approved

    Sea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”

    Synonyms: bay saltProducts: S Panax Liquidsoap, S Panax All In One Liquidsoap
  8. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

  9. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  10. Drug

    Melanoma antigen recognized by T-cells 1

    go.drugbank.com/drugs/DB15081
    Investigational

    Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

    Synonyms: Melanoma antigen recognized by T-cells 1